Galmed Pharmaceuticals Ltd. (GLMD) Form 6-K — Sep 8, 2026
Galmed Pharmaceuticals regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2), with the Nasdaq Listing Qualifications Staff confirming on September 3, 2026 that the matter is now closed and the ordinary shares will continue to be listed and traded. The company had been notified on January 29, 2026 that it failed to maintain a $1.00 minimum closing bid for 30 consecutive trading days, and it did not cure the deficiency during the initial 180-calendar-day period ending July 28, 2026, receiving a second 180-day period instead.
Key figures
- Cure Window
- 2026-08-20 to 2026-09-02
- Minimum Bid Price Usd
- 1
- Initial Cure Deadline
- 2026-07-28
- Compliance Period Days
- 180
- Deficiency Notice Date
- 2026-01-29
- Compliance Regained Notice Date
- 2026-09-03
- Consecutive Trading Days Required
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.